Ain Holdings Inc. · TSE:9627
Ain — Q1 FY4/26 Earnings Presentation
18 slides from Ain's earnings presentation, Sep 11, 2025
Slide 1: FY4/26 1Q IR Presentation
FY4/26 1Q IR PRESENTATION September 11, 2025
Slide 2: Results Overview
Results Overview © AIN HOLDINGS INC. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L Net sales increased 28.3% YoY and 1.5% against the plan due to growth at existing stores and stores opened in the previous year in both businesses, as well as supported by the consolidation of Francfranc in the previous fiscal year. Ordinary profit increased 43.4% YoY and 6.6% again
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business (Consolidated) Net sales increased 18.2% YoY and 2.2% against the plan because the number of prescriptions remained steady and average prescription price rose due to an increase in high-cost prescriptions. Segment profit decreased 0.3% YoY and increased 6.8% against the
Slide 5: Retail Business (Consolidated)
Retail Business (Consolidated) Net sales up 141.2% YoY and decreased 1.8% against the plan, supported by the consolidation of Francfranc in the previous fiscal year. Segment profit increased 186.6% YoY and 8.3% against the plan due to cost reduction. FY4/25 1Q FY4/26 1Q FY4/26 1Q YoY YoY Vs （¥ milli
Slide 6: Consolidated B/S
Consolidated B/S Net cash became ¥ (11,211) million due to funds procured for the acquisition of shares associated with the consolidation of Francfranc in the previous fiscal year through borrowings, but the shareholders’ equity ratio was 42.6%, maintaining a sound financial structure. End-FY4/25 En
Slide 7: Assets
Assets The balance of total assets increased ¥21,599 million from the end of the fiscal 2025, mainly reflecting increases in cash and deposits. , and decrease in accounts receivable – trade End-FY4/25 1Q and goodwill, etc. End-FY4/25 End-FY4/26 1Q Change (¥ million) Cash and deposits 49,404 26,881 4
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets Short-term and long-term borrowings increased ¥18,771 million mainly due to short-term borrowings to secure cash on hand. (¥ million) End-FY4/25 1Q End-FY4/25 End-FY4/26 1Q Change Accounts payable – trade 70,484 80,895 84,222 +3,327 Short-term borrowings 3,385 12,151 31,91
Slide 9: Review
Review © AIN HOLDINGS INC. All Rights Reserved. 8
Slide 10: Consolidated (YoY results)
Consolidated (YoY results) Ordinary profit increased ¥1.3 billion YoY due to the full-year contribution of Francfranc in retail business. Net sales Ordinary profit ¥103.6 billion ¥132.9 billion +¥29.3 billion ¥2.9 billion ¥4.2 billion +¥1.3 billion +28.3% +43.4% ■ Dispensing ■ Dispensing pharmacy ph
Slide 11: Consolidated (vs Plan)
Consolidated (vs Plan) Ordinary profit increased ¥0.3 billion against the plan because average prescription price rose due to an increase in high-cost prescriptions in dispensing pharmacy business, and increase in sales of high gross margin products in retail business. Net sales Ordinary profit ¥131
Slide 12: Number of Pharmacies and Stores
Number of Pharmacies and Stores ■ Plan and Results FY4/26 1Q FY4/26 Plan Results Plan Dispensing pharmacy 22 23 901 Organic 12 13 35 M&A 10 10 866 Opening Retail 5 6 26 AINZ & TULPE 5 6 20 Francfranc - - 6 Total 27 29 927 Dispensing Pharmacy 10 11 30 Closure Retail 2 1 10 Total 12 12 40 ■ Transition
Slide 13: Revised Plan
Revised Plan © AIN HOLDINGS INC. All Rights Reserved. 12
Slide 14: FY4/26 Plan (Dispensing Pharmacy Business)
FY4/26 Plan (Dispensing Pharmacy Business) The group forecasts net sales increase 43.3% YoY and segment profit increase 33.0% YoY due to the contribution of Sakura Pharmacy Group that joined the Group. FY4/25 FY4/26 FY4/26 YoY YoY （¥ million） results initial plan revised plan change change(%) Net sa
Slide 15: FY4/26 Plan (Retail Business)
FY4/26 Plan (Retail Business) The group forecasts net sales increase 36.1% YoY and segment profit increase 56.1% YoY due to the sales of AINZ&TULPE remained firm, in addition to the Francfranc contribution to the full year. FY4/25 FY4/26 FY4/26 YoY YoY （¥ million） results initial plan revised plan c
Slide 16: FY4/26 Plan (Consolidated)
FY4/26 Plan (Consolidated) The group forecasts net sales for the fiscal year ending April 30, 2026 increase 41.4% YoY and ordinary profit increase 46.6% YoY, due to the revision of the pharmacy business results from the contribution of Sakura Pharmacy Group. FY4/25 FY4/26 FY4/26 YoY YoY （¥ million）
Slide 17: Inquiries / Corporate Planning Division
Inquiries related to this presentation should be addressed to AIN HOLDINGS INC. Corporate Planning Division TEL: +81-3-5333-1812 https://www.ainj.co.jp/corporate/ This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been
Slide 18: AIN GROUP
AIN GROUP